Evidence map›Paper›PMID 36310147›Full record

ArticleChemMedChem2023

Imidazolylpyrrolone-Based Small Molecules as Anticancer Agents for Renal Cell Carcinoma.

Ana Sousa, Olívia Pontes, Juliana Andrade, Fátima Baltazar, Marta Costa, Fernanda Proença

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ana SousaChemistry Department, University of Minho, Campus de Gualtar, Braga, Portugal.
Olívia PontesLife and Health Sciences Research Institute (ICVS), University of Minho, Campus de Gualtar, Braga, Portugal.
Juliana AndradeChemistry Department, University of Minho, Campus de Gualtar, Braga, Portugal.
Fátima BaltazarLife and Health Sciences Research Institute (ICVS), University of Minho, Campus de Gualtar, Braga, Portugal.
Marta CostaLife and Health Sciences Research Institute (ICVS), University of Minho, Campus de Gualtar, Braga, Portugal.
Fernanda ProençaChemistry Department, University of Minho, Campus de Gualtar, Braga, Portugal.ORCID 0000-0002-5274-1949
University of Minho · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An in silico study focused on known cancer-related target proteins, identified a selection of imidazo[4,5-b]pyrrolo[3,4-d]pyridines as potentially active. These compounds were prepared by a novel synthetic approach, designed and developed in-house, based on the reaction of 5-amino-4-cyanoformimidoyl imidazoles with N-substituted cyanoacetamides. The substituted imidazolylpyrrolones obtained, were cyclized intramolecularly to generate the intended imidazo[4,5-b]pyrrolo[3,4-d]pyridines in a process catalyzed by DBU. Treating the imidazolylpyrrolones with an excess of triethyl orthoformate and heating at 80 °C in the presence of acid catalysis led to imidazopyrrolodiazepines. These compounds were screened for their anticancer potential, using the renal cell carcinoma cell line model (A498 and 786-O cell lines). Two compounds exhibited IC

Indexed as

Antineoplastic AgentsCarcinoma, Renal CellKidney NeoplasmsHumansImidazolesPyridinesAntineoplastic AgentsImidazolesPyridinesCyclizationImidazodiazepinesImidazolylpyrrolonesImidazopyridinesRenal cell carcinoma

Identifiers

PMID36310147
PMCPMC10098907
OpenAlexW4307776777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.